While the issue of access involves many factors, the articles in this issue of Journal of Clinical Pathways focus on costs and physical location, or setting, of cancer treatment.
Winston Wong, PharmD, Editor-in-Chief
As provider organizations come under increasing financial and competitive demands, there is pressure to drive expertise and health management into the community and frequently into patients’ own homes, to help reduce lengths of stay and admissions to acute care.
Winston Wong, PharmD, summarizes the articles appearing in the latest issue of JCP, including new research utilizing real-world claims data of patients with mCRC, commentary on FDA guidance, and perspectives on CAR-T therapy infusion settings.
The Centers for Medicare and Medicaid Services just announced their reimbursement level for the new chimeric antigen receptor T-cell products.
The ongoing journey toward value-based care has led to innovations in care delivery and reimbursement. Many new concepts and strategies have evolved from concept to reality.
The goal of this supplement is to provide a clearer perspective of the impact of AML upon the health care system, as well as the benefit of an AML clinical pathway.
Making the transition from fee-for-service reimbursement to value-based models of care and payments will be slow and difficult.
The promise of CAR-T therapies as a potential cure for cancers and the pressure that this creates in the market will likely serve to highlight the ineffective areas in our health care system, as providers contend with multiple barriers associated with the therapy.
It is an exciting time in oncology care as innovative cellular and gene therapies come to market, with many more to come in the near future.
Together, the articles in this issue emphasize the continued importance of not getting so carried away with technology, pre-approved plans, or theoretically ideal outcomes that the human aspect of medical care and care providers is lost.